Vesilute

Vesilute is a synthetic dipeptide with the sequence Lys-Glu (KE) and a molecular weight of approximately 275 Da. It was identified as a vascular system-specific bioregulator through Prof. Vladimir Khavinson's systematic screening of ultra-short peptides for organ-specific gene-regulatory activity at the Saint Petersburg Institute of Bioregulation and Gerontology. The KE dipeptide was isolated from young vascular tissue extracts and found to restore gene expression patterns in aged endothelial cells toward profiles characteristic of younger tissue.

The mechanism of action, like other Khavinson bioregulators, involves direct interaction with DNA rather than cell surface receptor signaling. Molecular modeling and fluorescence studies demonstrate that the KE dipeptide penetrates cell membranes and the nuclear envelope, where it binds to specific sequences in the minor groove of double-stranded DNA, modulating transcription factor access to promoter regions of vascular genes. This gene-regulatory mechanism explains why the effects of a single treatment course persist for months after the peptide itself has been cleared from circulation.

In aged human endothelial cell cultures, Vesilute normalized the expression of several critical vascular genes: eNOS (endothelial nitric oxide synthase, the enzyme producing the vasodilator and anti-atherogenic molecule NO), VEGF (vascular endothelial growth factor, which maintains the endothelial lining and promotes angiogenesis), and von Willebrand factor (a glycoprotein mediating platelet adhesion and coagulation). It also reduced expression of adhesion molecules ICAM-1 (intercellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1), which recruit inflammatory leukocytes to the vessel wall in the early stages of atherosclerotic plaque formation.

Clinical studies in elderly patients (age 60-75) demonstrated measurable improvements in vascular function. Laser Doppler flowmetry showed improved microcirculation parameters (increased perfusion in dermal capillary beds). Pulse wave velocity (PWV), the gold-standard non-invasive measure of arterial stiffness, was reduced, indicating improved arterial compliance. Exercise tolerance on standardized treadmill protocols improved. These clinical effects developed over 2-4 weeks of treatment and persisted for 3-6 months after discontinuation, consistent with the gene-regulatory mechanism producing lasting epigenetic changes rather than transient pharmacological effects.

As a dipeptide of only 275 Da, Vesilute has near-perfect oral bioavailability, since dipeptides are efficiently absorbed by the intestinal PepT1 transporter and are too small to be degraded by most endopeptidases. It is completely non-immunogenic (far below the 1500 Da threshold for MHC binding) and has no known drug interactions. It can be administered orally, sublingually, or by injection.

Storage is straightforward: the dipeptide is exceptionally stable in the dry state and can be stored at room temperature for months without degradation. For long-term storage, 2-8C is recommended. Reconstituted solutions should be kept at 2-8C and used within 30 days. Stable across a broad pH range (3-9).

Safety observations from clinical use show no adverse effects. In 28-day repeated-dose toxicity studies in rats at doses up to 100x the therapeutic level, no changes in body weight, organ histology, hematology, or blood chemistry were observed. No mutagenicity was detected in Ames testing. Clinical use in elderly patients produced no adverse events. The bioregulatory mechanism (normalizing gene expression rather than forcing it in one direction) inherently limits the possibility of overshoot effects.